TICKERNERD
Menu
LXRXLXRXHealthcare · Biotechnology

LXRX Stock Forecast: Lexicon Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$1.42
−4.05% on the day

The 6 Wall Street analysts covering Lexicon Pharmaceuticals, Inc. hold a median 12-month price target of $4.55 — +220.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 31 Oct 2026 — in the upper half.

Market cap
$658.5M
Ticker Nerd rank
65/ 100
Median analyst target
$4.55
Analysts covering
6
Revenue$692K−97.6% y/y
Operating income−$26.5M
Net income−$31.8M
Free cash flow−$9.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
0.0%
1M
−24.5%
YTD
+23.5%
1Y
+6.0%
From 52W high
−46.2%
From 52W low
+24.6%
$1.14
$2.64
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LXRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Lexicon Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
65/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
89
Value
75
Momentum
75
Volatility
56
Growth
51
Size
49
Issuance
47
Accruals
44
Revisions
40

Quality (89): The business earns solid, repeatable profits on what it owns.

Revisions (40): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

LXRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LXRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00Jan 26Apr 26Jul 26Oct 26LXRXHigh $8.00Median $4.55Low $1.69

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
4 Buy2 Hold0 Sell
Low $1.69Median $4.55High $8.00

The green dot is the last close — the median target sits +220.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
28 Sept 2026Cantor FitzgeraldInitiatesOverweight$8.00
11 May 2026CitigroupMaintainsBuy$2.30 → $3.10
11 May 2026CitigroupMaintainsBuy—
23 Mar 2026HC Wainwright & Co.ReiteratesBuy—
10 Mar 2026CitigroupMaintainsBuy—
5 Mar 2026HC Wainwright & Co.MaintainsBuy—
2 Sept 2025HC Wainwright & Co.ReiteratesBuy—
7 Aug 2025CitigroupMaintainsBuy—
24 June 2025HC Wainwright & Co.ReiteratesBuy—
28 Mar 2025HC Wainwright & Co.ReiteratesBuy—
7 Mar 2025HC Wainwright & Co.ReiteratesBuy—
7 Mar 2025NeedhamReiteratesHold—
7 Mar 2025Piper SandlerMaintainsOverweight—
4 Mar 2025Leerink PartnersDowngradeMarket Perform—
3 Mar 2025HC Wainwright & Co.ReiteratesBuy—
3 Mar 2025NeedhamReiteratesHold—
29 Jan 2025HC Wainwright & Co.ReiteratesBuy—
29 Jan 2025NeedhamReiteratesHold—
23 Dec 2024NeedhamReiteratesHold—
25 Nov 2024NeedhamReiteratesHold—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

LXRX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

LXRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Lexicon Pharmaceuticals, Inc. returned +6.0% against +12.4% for the S&P 500, dividends included.

LXRX vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Jan 26Apr 26Jul 26Oct 26LXRXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LXRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Lexicon Pharmaceuticals, Inc. (LXRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−9.9×

Cheaper than 94% of US stocks

Price / sales
15.2×

Cheaper than 10% of US stocks

Price / book
3.6×

Cheaper than 26% of US stocks

EV / EBITDA
−9.8×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
−97.6%

Higher than 2% of US stocks

Earnings growth (YoY)
−97.6%

Higher than 2% of US stocks

Gross margin
94.4%

Higher than 98% of US stocks

Operating margin
−3835.3%

Higher than 3% of US stocks

Net margin
−147.4%

Higher than 4% of US stocks

Returns & dividend
Return on equity
−40.2%

Higher than 24% of US stocks

Return on assets
−14.3%

Higher than 23% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Lexicon Pharmaceuticals, Inc. (LXRX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Lexicon Pharmaceuticals, Inc. has a market value of $658.5M and an enterprise value of $527.2M.

  • Revenue in the twelve months to 30 June 2026: $41.5M. The latest quarter shrank 97.6% year on year.

  • Net income over the same four quarters: −$61.1M, a −147.4% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.15.

  • Free cash flow in the twelve months to 30 June 2026: −$65.0M.

  • Shares outstanding: 444.9M.

  • Trailing P/E: −9.9×; forward P/E: −7.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Lexicon Pharmaceuticals, Inc. employs 81 people — $512K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 30 Oct 2026

Data provided by Twelve Data

Peers

LXRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LXRXLexicon Pharmaceuticals, Inc.$658.5M65
AURAAura Biosciences, Inc.$634.8M46
IMMXImmix Biopharma, Inc.$636.7M36
SLDBSolid Biosciences, Inc.$651.8M42
CADLCandel Therapeutics, Inc.$610.1M45
OLMAOlema Pharmaceuticals, Inc.$610.1M28
FDMT4D Molecular Therapeutics, Inc.$657.4M58

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Lexicon Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LXRX news & analysis

Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026

GlobeNewsWire · 29 Oct 2026neutral

Lexicon Pharmaceuticals announced that it will report third-quarter 2026 financial results before market open on November 5, 2026. Management will discuss the results and provide a business update on a conference call and live webcast at 8:30 a.m. ET that day.

Why it matters — LXRX watchers can note the scheduled date and time for the company's financial results and business update.

Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy

GlobeNewsWire · 23 Oct 2026neutral

Lexicon Pharmaceuticals provided an update on baseline patient characteristics in the pivotal Phase 3 SONATA-HCM study of sotagliflozin for symptomatic hypertrophic cardiomyopathy. The company said demographics were consistent with prior HCM agent studies and real-world practice, while the mean baseline KCCQ-CSS of 59 indicated considerable symptom burden.

Why it matters — The update offers LXRX watchers context on the study population and participants’ symptom burden at entry.

Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin's Biological Effects in Cardiovascular Disease

GlobeNewsWire · 21 Oct 2026positive

Lexicon announced publication of two preclinical studies reporting favorable effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy, and inhibitory effects on platelet activity and thrombus formation. The company said the findings provide further insight into the biology of dual SGLT1 and SGLT2 inhibition.

Why it matters — The results add preclinical evidence about sotagliflozin’s effects in cardiovascular pathways relevant to LXRX watchers.

Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More

Seeking Alpha · 30 Sept 2026positive

Lexicon Pharmaceuticals was upgraded to Buy based on multiple near-term catalysts across its pipeline. The company anticipates NDA resubmission for ZYNQUISTA in type 1 diabetes by Q4 2026, contingent on STENO1 safety data, and expects top-line results from the pivotal Phase 3 SONATA-HCM trial for sotagliflozin in HCM in Q1 2027.

Why it matters — LXRX watchers would care because the company's pipeline has emerging near-term milestones, including an expected NDA resubmission and pivotal Phase 3 trial data readouts.

Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today

The Motley Fool · 28 Sept 2026positive

Lexicon Pharmaceuticals stock rose by almost 6% today. According to a report, an analyst considers the stock a clear buy at current prices and believes sotagliflozin has strong potential to gain FDA approval for a new indication.

Why it matters — LXRX watchers would care because positive analyst sentiment and the potential FDA approval of sotagliflozin for a new indication could be significant for the company's pipeline and prospects.

FAQ

Frequently asked questions about LXRX stock

What is the LXRX stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Lexicon Pharmaceuticals, Inc. have a median 12-month price target of $4.55, with estimates ranging from $1.69 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LXRX stock a buy right now?

Of the 6 analysts covering Lexicon Pharmaceuticals, Inc., 4 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lexicon Pharmaceuticals, Inc. 65 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LXRX?

As at 31 Oct 2026, Lexicon Pharmaceuticals, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (89 of 100).

Will LXRX stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +220.4% from the last close, and Ticker Nerd's factor model ranks Lexicon Pharmaceuticals, Inc. 65 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LXRX stock forecast for 2030?

No analyst covering Lexicon Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LXRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.69 to $8 over the next 12 months.

How has LXRX stock performed over the past year?

Lexicon Pharmaceuticals, Inc. returned +6.0% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Lexicon Pharmaceuticals, Inc. do?

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for human disease.

What is the latest news on LXRX?

The most recent item we track (GlobeNewsWire, 29 Oct 2026): "Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026". Lexicon Pharmaceuticals announced that it will report third-quarter 2026 financial results before market open on November 5, 2026. Management will discuss the results and provide a business update on a conference call and live webcast at 8:30 a.m. ET that day.

Company

About Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for human disease. The company’s current portfolio centers on therapies for cardiometabolic disorders, neuropathic pain, and other chronic conditions, with products and candidates spanning commercial, clinical, and preclinical stages. Its marketed medicine INPEFA (sotagliflozin) is used in cardiometabolic care, while development programs include pilavapadin for neuropathic pain and LX9851 for obesity and related metabolic disorders. Lexicon Pharmaceuticals also applies its gene-science and target-biology expertise to advance drug candidates aimed at genetically defined pathways, reflecting a research-driven model that links discovery with commercialization. Headquartered in The Woodlands, Texas, Lexicon Pharmaceuticals serves the specialty pharmaceutical market through a focused pipeline designed for patients with serious, long-term medical needs.

CEO Dr. Michael S. Exton Ph.D. · 81 employees · United States · https://www.lexpharma.com